lisocabtagene maraleucel
AXP000016.1 · CAR-T cell therapy
- Platform
- autologous CAR-T
- Targets
- CD19
- Originator
- Juno Therapeutics
- Sponsor
- Bristol Myers Squibb
Names
| Name | Type | Source |
|---|---|---|
| lisocabtagene maraleucel | preferred name, INN | curator, ncit |
| Breyanzi | brand | ncit |
| JCAR017 | code | ncit |
| liso-cel | synonym | ncit |
Virus
- Role
- Ex vivo gene transfer
- Family
- Retroviridae
- Virus
- lentivirus
- Replication
- non replicating
- Modifications
- replication-incompetent lentiviral vector; FMC63-derived anti-CD19 scFv, IgG4 hinge, CD28 transmembrane domain, 4-1BB costimulatory domain, CD3 zeta signalling domain; the cells also express a non-functional truncated EGFR (EGFRt)
- Transgenes
- anti-CD19 chimeric antigen receptor, truncated EGFR (EGFRt)
- Route
- ex vivo, intravenous
- Carrier
- autologous CD8+ and CD4+ T cells, activated and transduced separately and supplied as two components making one dose
- Source
- evidence
Cross-references
- NCI Thesaurus
- C125192
- Wikidata
- Q105605102
- FDA UNII
- 7K2YOJ14X0
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| FDA | US | 2021-02-05 | approved | Breyanzi | Adults with large B-cell lymphoma after first-line chemoimmunotherapy failure or other listed criteria; relapsed or refractory CLL or SLL after two or more lines including a BTK and a BCL-2 inhibitor (accelerated approval); follicular lymphoma; mantle cell lymphoma; and marginal zone lymphoma. Not for primary CNS lymphoma | source |
| PMDA | JP | 2021-03-22 | approved | Breyanzi | Relapsed or refractory large B-cell lymphoma (diffuse large B-cell, primary mediastinal large B-cell, transformed indolent non-Hodgkin and high-grade B-cell lymphoma) and relapsed or refractory follicular lymphoma, in patients not previously given CD19-directed CAR T cells | source |
| EMA | EU | 2022-04-04 | approved | Breyanzi | Adults with DLBCL, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma or grade 3B follicular lymphoma refractory to or relapsing within 12 months of first-line chemoimmunotherapy, or after two or more lines; and relapsed or refractory mantle cell lymphoma after at least two lines including a BTK inhibitor | source |
Clinical trials (36)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07194980 | Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Recruiting | Phase 2 | 2026-12-01 | 2029-10-20 | 20 | Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
| NCT07725406 | Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma | Recruiting | Phase 1 | 2026-11 | 2028-08-01 | 32 | Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed or Refractory Multiple Myeloma (MM) |
| NCT07711483 | GLORY: Glofit-GemOx With Liso-Cel For Lymphoma | Recruiting | Phase 2 | 2026-09-15 | 2028-09-15 | 56 | B-cell Lymphomas; Large B-cell Lymphoma; Lymphoma; Relapsed/Refractory Large B-cell Lymphoma |
| NCT07777120 | Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma | Active not recruiting | 2026-03-24 | 2048-03-31 | 300 | Marginal Zone Lymphoma | |
| NCT07316010 | Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma | Recruiting | Phase 2 | 2026-03-17 | 2029-03-21 | 50 | Large B-cell Lymphoma |
| NCT07052305 | NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma | Recruiting | Phase 1 | 2026-03-12 | 2027-11-30 | 24 | Large B-cell Lymphoma |
| NCT07188558 | A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | Recruiting | Phase 3 | 2026-01-12 | 2029-12 | 400 | Diffuse Large B Cell Lymphoma (DLBCL); Diffuse Large B Cell Lymphoma Refractory; Diffuse Large B Cell Lymphoma Relapsed; Large B-cell Lymphoma; Lymphoma, B-Cell; Non-Hodgkin Lymphoma; Non-Hodgkin Lymphoma Refractory/ Relapsed; Refractory Non-Hodgkin Lymphoma; Relapsed Non-Hodgkin Lymphoma |
| NCT07098364 | ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma | Suspended | Phase 1/2 | 2025-12-27 | 2030-10-04 | 33 | Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Grade 3b Follicular Lymphoma; Recurrent High-Grade B-Cell Lymphoma; Recurrent Indolent B-Cell Non-Hodgkin Lymphoma; Recurrent Primary Mediastinal Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Refractory Grade 3b Follicular Lymphoma; Refractory High-Grade B-Cell Lymphoma; Refractory Indolent B-Cell Non-Hodgkin Lymphoma; Refractory Primary Mediastinal Large B-Cell Lymphoma |
| NCT07015242 | A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma | Recruiting | Phase 2 | 2025-11-06 | 2028-01-09 | 65 | Lymphoma |
| NCT06794268 | A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting | Recruiting | 2025-02-04 | 2044-08-31 | 300 | Follicular Lymphoma | |
| NCT06788652 | A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting | Recruiting | 2025-02-04 | 2044-09-30 | 300 | Mantle Cell Lymphoma (MCL) | |
| NCT06788639 | A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting | Recruiting | 2025-02-04 | 2044-06-30 | 300 | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) | |
| NCT06550141 | Emapalumab Prevention of CAR-T Cell Associated Toxicities | Recruiting | Phase 2 | 2024-09-18 | 2027-08-01 | 28 | Diffuse Large B Cell Lymphoma; Follicular Lymphoma; High-grade B-cell Lymphoma; Large B-cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma; Refractory Non-Hodgkin Lymphoma; Relapsed Non-Hodgkin Lymphoma |
| NCT06313996 | A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma | Withdrawn | Phase 3 | 2024-03-29 | 2031-10-16 | 0 | Relapsed or Refractory Follicular Lymphoma |
| NCT06205290 | A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies | Withdrawn | Phase 3 | 2024-01-16 | 2031-10-13 | 0 | Leukemia, Lymphocytic, Chronic, B-Cell |
| NCT06357754 | Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy | Recruiting | 2023-10-06 | 2038-10-06 | 50 | Chronic Lymphocytic Leukaemia; Multiple Myeloma; Non-Hodgkin Lymphoma | |
| NCT05873712 | Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome | Recruiting | Phase 2 | 2023-07-28 | 2026-12-31 | 24 | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma; Recurrent Transformed Chronic Lymphocytic Leukemia; Recurrent Transformed Non-Hodgkin Lymphoma; Refractory Transformed; Refractory Transformed B-cell Non-Hodgkin Lymphoma; Refractory Transformed Chronic Lymphocytic Leukemia; Refractory Transformed Non-Hodgkin Lymphoma; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma |
| NCT05633615 | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Recruiting | Phase 2 | 2023-06-12 | 2030-06-30 | 396 | Diffuse Large B-Cell Lymphoma; Grade 3b Follicular Lymphoma; Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Transformed Follic Lymph to Diff Large B-Cell Lymphoma; Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma |
| NCT05672173 | Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation | Active not recruiting | Phase 2 | 2023-06-02 | 2027-08-24 | 9 | Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Transformed Chronic Lymphocytic Leukemia; Richter Syndrome |
| NCT05621096 | Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma | Active not recruiting | Phase 1 | 2023-03-21 | 2025-01-20 | 33 | DLBCL - Diffuse Large B Cell Lymphoma; Follicular Lymphoma; High-grade B-cell Lymphoma; Indolent B-Cell Non-Hodgkin Lymphoma; Mediastinal Large B-cell Lymphoma; Refractory Non-Hodgkin Lymphoma; Relapsed Non-Hodgkin Lymphoma |
| NCT05583149 | Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas | Active not recruiting | Phase 2 | 2023-03-01 | 2024-11-23 | 28 | Aggressive B-cell NHL; C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma; C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma; DLBCL, Nos Genetic Subtypes; De Novo or Transformed Indolent B-cell Lymphoma; Diffuse Large B-cell Lymphoma (DLBCL); EBV-Positive DLBCL, Nos; Grade 3b Follicular Lymphoma; High-Grade B-Cell Lymphoma, Nos; Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL); Refractory Aggressive B-cell Lymphomas; Refractory B-Cell Non-Hodgkin Lymphoma; T Cell/Histiocyte-rich Large B-cell Lymphoma |
| NCT05359211 | NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | Completed | Phase 1 | 2022-12-08 | 2025-09-04 | 27 | Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Grade 3b Follicular Lymphoma; Recurrent Primary Mediastinal Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Refractory Grade 3b Follicular Lymphoma; Refractory Primary Mediastinal Large B-Cell Lymphoma; Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma |
| NCT05075603 | Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy | Completed | Phase 1 | 2021-07-29 | 2024-12-18 | 17 | DLBCL Arising From Follicular Lymphoma; High-grade B-cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-cell Lymphoma |
| NCT04855253 | Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL | Suspended | Phase 1/2 | 2021-06-09 | 2027-09 | 30 | DLBCL; DLBCL Arising From Follicular Lymphoma; Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma |
| NCT04245839 | A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) | Active not recruiting | Phase 2 | 2020-07-14 | 2031-09-30 | 276 | Lymphoma, Non-Hodgkin |
| NCT03642626 | MT2017-45: CAR-T Cell Therapy for Heme Malignancies | Active not recruiting | Phase 2 | 2018-12-18 | 2024-02-09 | 150 | Acute Lymphoblastic Leukemia; Large B-cell Lymphoma |
| NCT03744676 | A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) | Completed | Phase 2 | 2018-11-29 | 2023-09-22 | 104 | Immune System Disorder; Immunoproliferative Disorders; Lymphatic Diseases; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Neoplasms; Neoplasms by Histologic Type |
| NCT03575351 | A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas | Completed | Phase 3 | 2018-10-23 | 2023-10-23 | 184 | Lymphoma, Non-Hodgkin |
| NCT03743246 | A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | Terminated | Phase 1/2 | 2018-10-17 | 2024-01-26 | 21 | Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
| NCT03483103 | Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) | Completed | Phase 2 | 2018-07-27 | 2021-09-24 | 74 | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, Nonhodgkin |
| NCT03484702 | Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma | Completed | Phase 2 | 2018-06-05 | 2023-12-15 | 113 | Lymphoma, Non-Hodgkin |
| NCT03436771 | Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | Terminated | 2018-02-19 | 2018-07-20 | 4 | Chronic Lymphocytic Leukemia; Diffuse Large B Cell Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma; Non Hodgkin Lymphoma | |
| NCT03310619 | A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies | Completed | Phase 1/2 | 2017-12-20 | 2023-02-15 | 62 | Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin |
| NCT03331198 | Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | Active not recruiting | Phase 1/2 | 2017-11-27 | 2027-11-26 | 320 | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Small Lymphocytic |
| NCT02631044 | Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | Completed | Phase 1 | 2016-01-06 | 2024-05-16 | 387 | Diffuse Large B Cell Lymphoma; Follicular Lymphoma; Mantle-cell Lymphoma; Non-Hodgkin Lymphoma; Primary Mediastinal B-cell Lymphoma |
| NCT04400591 | Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol | Available | Lymphoma, Large B-Cell, Diffuse |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41033998 | Tumor Inflammation-associated Neurotoxicity Following CD19-targeted Chimeric Antigen Receptor T-cell Therapy in a Patient with High-grade B-cell Lymphoma. | Internal medicine (Tokyo, Japan) | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 41692020 | Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study. | Lancet (London, England) | 2026 | cited by trial NCT04245839 |
| PMID 41765136 | Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma. | Transplantation and cellular therapy | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 41765468 | CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma in a nonagenarian patient. | Journal of clinical and experimental hematopathology : JCEH | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 41836222 | Case Report: CAR-T therapy for relapsed diffuse large B-cell lymphoma in a patient with pre-existing Parkinson's disease-unfolding clinical challenges. | Frontiers in oncology | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 41853416 | Successful Use of Chimeric Antigen Receptor T-cell (CAR-T) Therapy With Lisocabtagene Maraleucel in a Renal Transplant Recipient With Refractory/Relapsed Diffuse Large B-Cell Lymphoma (DLBCL). | Cureus | 2026 | name in title: lisocabtagene maraleucel |
| PMID 42044466 | Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2026 | cited by trial NCT03575351 |
| PMID 42178058 | Impact of ASTCT Toxicity Grading System on Outcomes After CAR-T for Mature B-Cell Malignancies. | Transplantation and cellular therapy | 2026 | name in abstract: liso-cel |
| PMID 42237652 | Five-year survival outcomes of lisocabtagene maraleucel in R/R LBCL from the TRANSCEND NHL 001 study. | Blood | 2026 | cited by trial NCT02631044 |
| PMID 42285354 | Impact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma. | Transplantation and cellular therapy | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42462111 | Durable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL. | Blood | 2026 | cited by trial NCT04245839 |
| PMID 42520199 | Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004. | Blood | 2026 | name in title: lisocabtagene maraleucel |
| PMID 42669548 | A case of diffuse large B-cell lymphoma achieving complete remission with epcoritamab after pseudoprogression. | Journal of clinical and experimental hematopathology : JCEH | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42875607 | Efficacy and safety of lisocabtagene maraleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: 31-month follow-up of the phase 2 TRANSCEND FL study. | International journal of clinical oncology | 2026 | cited by trial NCT04245839 |
| PMID 42908725 | Case Report: Durable, well-tolerated complete response to epcoritamab plus pirtobrutinib in Richter transformation relapsing after CD19 CAR T-cell therapy. | Frontiers in medicine | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42909844 | Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel as Second-Line Treatment for Large B Cell Lymphoma in the United States. | Advances in therapy | 2026 | cited by trial NCT03575351 |
| PMID 39479862 | Comparative efficacy of lisocabtagene maraleucel in the PILOT study versus second-line chemotherapy regimens in the real world. | Haematologica | 2025 | cited by trial NCT03483103 |
| PMID 39580347 | Implementation of a lisocabtagene maraleucel chimeric antigen receptor T-cell therapy outpatient monitoring program: Multicenter nursing/advanced practice provider perspectives. | Seminars in oncology nursing | 2025 | name in title: lisocabtagene maraleucel |
| PMID 39657136 | Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis. | Blood advances | 2025 | name in title: lisocabtagene maraleucel |
| PMID 39938007 | Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma. | Blood | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 40025178 | Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study. | Bone marrow transplantation | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 40305658 | Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study. | Blood advances | 2025 | cited by trial NCT03483103 |
| PMID 40589238 | Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experience. | British journal of haematology | 2025 | name in abstract: liso-cel |
| PMID 40623279 | Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | cited by trial NCT03575351 |
| PMID 40663365 | FDA Approval Summary: Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2025 | name in title: lisocabtagene maraleucel |
| PMID 40708270 | Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma. | Leukemia & lymphoma | 2025 | name in title: lisocabtagene maraleucel |
| PMID 40815804 | Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma. | Blood advances | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 41016810 | Schizophyllum commune infection following chimeric antigen receptor T-cell therapy in a patient with lymphoma. | Journal of clinical and experimental hematopathology : JCEH | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 41117994 | Peripheral T cell lymphoma following CD19-targeted chimeric antigen receptor T cell therapy. | International journal of hematology | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 37646670 | Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study. | Haematologica | 2024 | cited by trial NCT03483103 |
| PMID 37890149 | Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. | Blood | 2024 | cited by trial NCT02631044 |
| PMID 38072625 | Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024 | cited by trial NCT02631044 |
| PMID 38324398 | FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2024 | name in title: lisocabtagene maraleucel |
| PMID 38547003 | Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen. | Future oncology (London, England) | 2024 | cited by trial NCT03575351 |
| PMID 38552193 | Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024 | name in abstract: lisocabtagene maraleucel |
| PMID 38802271 | Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China. | Journal for immunotherapy of cancer | 2024 | name in abstract: lisocabtagene maraleucel |
| PMID 38830991 | Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. | Nature medicine | 2024 | cited by trial NCT04245839 |
| PMID 38854403 | A case of successful CAR-T cell therapy for early isolated CNS recurrence of DLBCL with persistent CAR-T cells. | Blood cell therapy | 2024 | name in abstract: lisocabtagene maraleucel |
| PMID 39347584 | OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL. | Blood advances | 2024 | cited by trial NCT03744676 |
| PMID 36542826 | Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. | Blood | 2023 | cited by trial NCT03575351 |
| PMID 36575360 | CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review. | Bone marrow transplantation | 2023 | name in abstract: lisocabtagene maraleucel |
| PMID 36755418 | Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma. | Leukemia & lymphoma | 2023 | cited by trial NCT02631044 |
| PMID 37295445 | Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. | Lancet (London, England) | 2023 | cited by trial NCT03331198 |
| PMID 37544410 | Estimating the Cost per Clinical Outcome of Second-Line Liso-Cel Versus Autologous Stem Cell Transplantation in Patients with Transplantation-Intended Relapsed/Refractory Large B Cell Lymphoma. | Transplantation and cellular therapy | 2023 | cited by trial NCT03575351 |
| PMID 37873752 | Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt's Lymphoma. | Medical sciences (Basel, Switzerland) | 2023 | name in abstract: lisocabtagene maraleucel |
| PMID 38022532 | Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models. | Frontiers in immunology | 2023 | cited by trial NCT04855253 |
| PMID 34699592 | Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. | Blood | 2022 | cited by trial NCT03331198 |
| PMID 35156195 | In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma. | Clinical pharmacology and therapeutics | 2022 | cited by trial NCT02631044 |
| PMID 35337365 | Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel. | Experimental hematology & oncology | 2022 | cited by trial NCT02631044 |
| PMID 35610089 | Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications. | Cytotherapy | 2022 | cited by trial NCT02631044 |
| PMID 35619325 | Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. | Cancer medicine | 2022 | name in title: lisocabtagene maraleucel |
| PMID 35717989 | Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. | Lancet (London, England) | 2022 | cited by trial NCT03575351 |
| PMID 35839786 | Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. | The Lancet. Oncology | 2022 | cited by trial NCT03483103 |
| PMID 36149968 | Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL. | Blood advances | 2022 | name in title: lisocabtagene maraleucel |
| PMID 33288485 | Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. | Clinical lymphoma, myeloma & leukemia | 2021 | cited by trial NCT03575351 |
| PMID 33720336 | Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial. | Blood advances | 2021 | cited by trial NCT02631044 |
| PMID 33904895 | Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma. | Blood advances | 2021 | cited by trial NCT02631044 |
| PMID 33970454 | Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1. | Advances in therapy | 2021 | cited by trial NCT02631044 |
| PMID 34125421 | Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma. | Clinical pharmacokinetics | 2021 | cited by trial NCT02631044 |
| PMID 34310745 | Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. | American journal of hematology | 2021 | cited by trial NCT02631044 |
| PMID 34493319 | Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma. | Journal of hematology & oncology | 2021 | cited by trial NCT02631044 |
| PMID 34515338 | Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. | The Cochrane database of systematic reviews | 2021 | cited by trial NCT02631044 |
| PMID 32888407 | Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. | Lancet (London, England) | 2020 | cited by trial NCT02631044 |
Other papers
Preclinical studies, reviews and other papers that name it, newest 100 shown.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39410883 | Neurotoxicity associated with chimeric antigen receptor T-cell therapy: a real-world study leveraging the FDA Adverse Event Reporting System. | Expert opinion on drug safety | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 40373976 | Health and Economic Impact of Vein-to-Vein Time in CAR T-Cell Therapy in the Second-Line Treatment of Relapsed/Refractory Large B-Cell Lymphoma: A US Cost-Effectiveness Analysis. | Transplantation and cellular therapy | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 40968610 | Effectiveness of CAR-T Cell Therapies for Relapsed/Refractory Follicular Lymphoma: An External Control Arm Study. | Cancer research and treatment | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 41138816 | Who Is Eligible for Chimeric Antigen Receptor T Cell Therapy? Expert Perspectives on Overcoming Referral Barriers. | Transplantation and cellular therapy | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 41183747 | Comparative Analysis of Lymphodepletion Regimens in CART-19 Treatment for Relapsed/Refractory Diffuse Large B Cell Lymphoma. | Transplantation and cellular therapy | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 41207679 | T-Cell-Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions. | European journal of haematology | 2026 | name in abstract: liso-cel |
| PMID 41235976 | CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting. | Transplantation and cellular therapy | 2026 | name in title: lisocabtagene maraleucel |
| PMID 41317374 | Successful treatment of refractory DLBCL coexisting with SLE using Liso-cel, complicated by cytokine release syndrome. | Rheumatology (Oxford, England) | 2026 | name in title: liso-cel |
| PMID 41345759 | Comparative Economic Evaluations of CAR-T Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Systematic Review. | PharmacoEconomics | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 41391508 | Immune Effector Cell-Associated HLH-Like Syndrome (IEC-HS) in CAR-T and TCE-Treated Myeloma and B-Cell Malignancies: Insights from a Pharmacovigilance Study. | Transplantation and cellular therapy | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 41396346 | Cost-Effectiveness of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Blood Cancers: An Updated Systematic Review. | PharmacoEconomics - open | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 41483380 | Safety and effectiveness of lisocabtagene maraleucel following PD-1 blockade in relapsed or refractory PMBCL. | International journal of hematology | 2026 | name in title: lisocabtagene maraleucel |
| PMID 41492445 | Efficacy and safety of chimeric antigen receptor T-cell therapy in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysis. | Therapeutic advances in hematology | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 41504990 | Real-world effectiveness and safety of lisocabtagene maraleucel for relapsed/refractory large B cell lymphoma in Japan. | International journal of clinical oncology | 2026 | name in title: lisocabtagene maraleucel |
| PMID 41529329 | Impact of CD5 expression on outcomes for chimeric antigen receptor-T cell therapy in relapsed and refractory diffuse large B-cell lymphoma. | Cytotherapy | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 41651792 | Cost-Effectiveness Analysis of Second-Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B-Cell Lymphoma. | European journal of haematology | 2026 | name in title: lisocabtagene maraleucel |
| PMID 41698482 | Hypogammaglobulinemia at Leukapheresis Predicts Delayed Humoral Immune Reconstitution and Increased Risk of Infections After CD19 CAR-T for B-Cell Lymphoma. | Transplantation and cellular therapy | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 41707107 | Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM. | Blood advances | 2026 | name in title: lisocabtagene maraleucel |
| PMID 41748023 | Association Between Patient-Reported Outcomes Prior to Chimeric Antigen Receptor (CAR) T-Cell Therapy and Clinical Outcomes. | Transplantation and cellular therapy | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 41760136 | Lisocabtagene Maraleucel. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists | 2026 | name in title: lisocabtagene maraleucel |
| PMID 41762956 | Low reticulocyte count at infusion is a risk factor for ICANS in CAR-T cell therapy. | Cytotherapy | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 41774434 | A new era for transplant-ineligible R/R LBCL patients: what's changing? | Leukemia & lymphoma | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 41774517 | Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma. | Blood | 2026 | name in title: lisocabtagene maraleucel |
| PMID 41776243 | Lisocabtagene maraleucel has high efficacy in R/R MZL. | Nature reviews. Clinical oncology | 2026 | name in title: lisocabtagene maraleucel |
| PMID 41777657 | Advancing access to CAR T-cell therapy: insights and real-world experience from a community oncology practice. | Frontiers in oncology | 2026 | name in abstract: liso-cel |
| PMID 41825137 | NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026. | Journal of the National Comprehensive Cancer Network : JNCCN | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 41828393 | Harnessing CAR-Extracellular Vesicles for Next-Generation Cancer Immunotherapy. | International journal of molecular sciences | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 41934060 | Current Treatment of Double Refractory Chronic Lymphocytic Leukemia: A Focus on Novel Drugs. | Clinical lymphoma, myeloma & leukemia | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 41935576 | Neurotoxicity in Older Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy: A Multicenter Study. | Transplantation and cellular therapy | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 41964291 | Impaired hematopoiesis affects apheresis and CAR T-cell product composition and treatment response. | Transfusion | 2026 | name in abstract: liso-cel |
| PMID 41968224 | Real-world outcomes of chimeric antigen receptor T-cell therapy with pembrolizumab as holding and/or bridging therapy in relapsed/refractory primary mediastinal large B-cell lymphoma. | International journal of clinical oncology | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42018609 | Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis. | Blood advances | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42050853 | Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphoma. | Leukemia & lymphoma | 2026 | name in title: lisocabtagene maraleucel |
| PMID 42052989 | Unraveling the care pathway for CAR T-cell therapy in large B-cell lymphoma: insights from a nationwide study in France (2018-2023). | Leukemia & lymphoma | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42081292 | A systematic analysis of the inherent dose uncertainty in autologous CAR T-cell products. | Journal of biopharmaceutical statistics | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42099680 | Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group. | HemaSphere | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42138782 | Indirect Treatment Comparisons of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in Third-Line or Later Relapsed or Refractory Follicular Lymphoma. | Advances in therapy | 2026 | name in title: lisocabtagene maraleucel |
| PMID 42140929 | Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy. | Nature communications | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42173255 | Prolonged Cytokine Release Syndrome is Associated with Hypofibrinogenemia after CD19-Directed CAR T-Cell Therapy in Adult Patients with Relapsed/Refractory Lymphoma. | Transplantation and cellular therapy | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42208766 | Delay differential equation modeling of CAR-T cellular kinetics: Application to BCMA-targeted (Ide-cel, Orva-cel) and CD19-targeted (Lisocel) therapies. | Journal of pharmaceutical sciences | 2026 | name in title: liso-cel |
| PMID 42225561 | Re: 'Cost-Effectiveness Analysis of Second-Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B-Cell Lymphoma'. | European journal of haematology | 2026 | name in title: lisocabtagene maraleucel |
| PMID 42265975 | Beyond Chemoimmunotherapy: Emerging Cellular and Targeted Therapies in Transformed Follicular Lymphoma: A Scoping Review. | Cancer control : journal of the Moffitt Cancer Center | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42279369 | Prophylactic Anakinra to Prevent Neurotoxicity After CAR T-Cell Therapy in Aggressive B-Cell Lymphomas: A Single-Center Real-World Experience. | Cancers | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42305450 | Comparative efficacy and safety of systemic therapies in transplant-eligible and ineligible relapsed/refractory large B-cell lymphoma: a Bayesian network meta-analysis. | Translational cancer research | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42329247 | Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma. | Oncology (Williston Park, N.Y.) | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42341926 | Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma. | Transplantation and cellular therapy | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42359427 | Durability Benchmarking of Contemporary Second-Line and Later Therapies for Relapsed or Refractory Follicular Lymphoma Using Reconstructed Individual Patient Data From Published Kaplan-Meier Curves. | Cureus | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42471153 | Transfusion support after CAR-T cell therapy: Real-world patterns across commercial products and disease groups. | Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42496442 | Efficacy and Safety of Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma: A Product-Specific Systematic Review and Meta-Analysis of Clinical Trials and Real-World Studies. | Hematology reports | 2026 | name in title: lisocabtagene maraleucel |
| PMID 42527721 | Follicular Lymphoma: Novel Therapies and Strategies for Optimal Therapeutic Sequencing. | Current oncology reports | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42534709 | Resolution of Paraneoplastic Cutaneous Angioendotheliomatosis After CAR T-Cell Therapy in TP53-Deleted CLL: A Case Report. | EJHaem | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42556536 | Impact of Prior Bendamustine Exposure on Chimeric Antigen Receptor T-Cell Therapy Outcomes in Follicular Lymphoma. | Transplantation and cellular therapy | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42566728 | Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42567965 | Effectiveness of anti-CD19 CAR T-cell therapy for high-grade B-cell lymphoma in Japan: a single-institution analysis. | International journal of clinical oncology | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42568509 | CD19 CAR-T cell therapy in large B-cell lymphoma: clinical evidence, resistance, toxicity, and precision strategies. | Frontiers in immunology | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42611409 | Clinical Pharmacology of Lisocabtagene Maraleucel in B-cell Malignancies. | Targeted oncology | 2026 | name in title: lisocabtagene maraleucel |
| PMID 42618274 | Late-onset Human Herpesvirus 6 Encephalitis with Secondary Hemophagocytic Lymphohistiocytosis after CAR T-cell Therapy. | Internal medicine (Tokyo, Japan) | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42625595 | Post-CAR T-cell thyroid dysfunction: destructive thyroiditis identified through thyroid function monitoring in a single-center cohort. | Frontiers in oncology | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42663433 | InflaMix Predicts Severe CRS, ICU Admission, and Progression-Free Survival After CAR-T Therapy in LBCL. | European journal of haematology | 2026 | name in abstract: liso-cel |
| PMID 42671910 | Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma. | Blood cancer discovery | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42753811 | B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. | Journal of the National Comprehensive Cancer Network : JNCCN | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42800585 | Real-World Comparison of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: A Target Trial Emulation. | Transplantation and cellular therapy | 2026 | name in title: lisocabtagene maraleucel |
| PMID 42807827 | Integrating new and "old" cellular therapies in the evolving landscape of relapsed or refractory large B-cell lymphoma. | Frontiers in oncology | 2026 | name in abstract: liso-cel |
| PMID 42821304 | Liso-cel delivers: is the debate over for 3L FL? | Blood | 2026 | name in title: liso-cel |
| PMID 42831097 | Safety Profile of Chimeric Antigen Receptor T-cell Therapies in Diffuse Large B-cell Lymphoma: An Analysis of Real-World Adverse Event Reporting From the FDA Adverse Event Reporting System. | Mayo Clinic proceedings. Innovations, quality & outcomes | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42844744 | Immune effector cell-associated neurotoxicity syndrome in hematological malignancy patients treated with CAR-T cell: A systematic review. | Journal of investigative medicine : the official publication of the American Federation for Clinical Research | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 42908664 | Comparative real-world pharmacovigilance analysis of adverse event signals associated with six approved CAR-T products using the FAERS database. | Frontiers in pharmacology | 2026 | name in abstract: Breyanzi |
| PMID 42950111 | Care pathway of patients with second-line large B-cell lymphoma treated with CAR T-cell therapies in France. | Leukemia & lymphoma | 2026 | name in abstract: lisocabtagene maraleucel |
| PMID 39418599 | Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network. | Blood advances | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 39462177 | Comparative Analysis of Bispecific Antibodies and CAR T-Cell Therapy in Follicular Lymphoma. | European journal of haematology | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 39546746 | A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma. | Blood advances | 2025 | name in title: lisocabtagene maraleucel |
| PMID 39666878 | Dynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell Lymphoma. | Blood cancer discovery | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 39779930 | T cell malignancies after CAR T cell therapy in the DESCAR-T registry. | Nature medicine | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 39784146 | Should CAR-T cell therapy be considered a standard of care for patients with refractory diffuse large B-cell lymphoma in second line treatment? | Expert opinion on biological therapy | 2025 | name in abstract: liso-cel |
| PMID 39846935 | Severe hypophosphatemia following idecabtagene vicleucel regardless of the severity of cytokine release syndrome. | Cytotherapy | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 39883946 | Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel. | Blood advances | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 39893244 | Treatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphoma. | Bone marrow transplantation | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 39941798 | Improving Treatment Options for Patients with Double Refractory CLL. | Cancers | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 39954961 | Impact of Real-World Clinical Factors on an Analysis of the Cost-Effectiveness of "Immediate CAR-T" Versus "Late CAR-T" as Second-Line Treatment for DLBCL Patients. | Transplantation and cellular therapy | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 39958356 | Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas. | Frontiers in immunology | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 39966627 | Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma. | Nature reviews. Clinical oncology | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 40045329 | Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma. | Experimental hematology & oncology | 2025 | name in title: lisocabtagene maraleucel |
| PMID 40066130 | Lisocabtagene Maraleucel for Richter's Transformation-A Case Series. | EJHaem | 2025 | name in title: lisocabtagene maraleucel |
| PMID 40079097 | Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow-up. | Haematologica | 2025 | name in title: lisocabtagene maraleucel |
| PMID 40163049 | Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States. | Journal of medical economics | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 40209064 | Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia. | Blood | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 40293655 | The Improving Outcomes in Relapsed-Refractory Diffuse Large B Cell Lymphoma: The Role of CAR T-Cell Therapy. | Current treatment options in oncology | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 40346502 | Hematologic and lymphatic disorders associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. | BMC cancer | 2025 | name in abstract: liso-cel |
| PMID 40486643 | Navigating the risks and benefits of newly approved Lisocabtagene Maraleucel in mantle cell lymphoma treatment. | Annals of medicine and surgery (2012) | 2025 | name in title: lisocabtagene maraleucel |
| PMID 40515863 | Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia. | Discover oncology | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 40590814 | Yield-driven approach optimizes apheresis of CD19 chimeric antigen receptor-T cell therapy for patients with lymphoma. | Cytotherapy | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 40658007 | Chimeric antigen receptor T-cell therapy in aggressive lymphomas. | Current opinion in oncology | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 40675858 | Management of Relapsed and/or Refractory Chronic Lymphocytic Leukemia. | Hematology/oncology clinics of North America | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 40689917 | Post-marketing Safety Assessment of CAR T-cell Therapies: Analysis of Individual Case Safety Reports in the VigiBase. | Therapeutic innovation & regulatory science | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 40714188 | Integrative population pharmacokinetic modeling of two BCMA-targeted and one CD19-targeted CAR-T therapies using full Bayesian inference with a student's t-based M3 censoring approach for robust handling of outliers and BLQ data. | Journal of pharmaceutical sciences | 2025 | name in abstract: liso-cel |
| PMID 40726603 | Low Occurrence of Ocular Adverse Events after CAR-T Cell Therapy. | Ocular oncology and pathology | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 40729699 | How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitor. | Blood | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 40754556 | Knowledge-map and bibliometric analysis of scientific research on FDA-approved Chimeric Antigen Receptor T cell products (2015-2024). | Discover oncology | 2025 | name in abstract: liso-cel |
| PMID 40902836 | From R-CHOP to revolution: How CAR T-Cells, ADCs, and bispecific antibodies are transforming DLBCL treatment. | Critical reviews in oncology/hematology | 2025 | name in abstract: lisocabtagene maraleucel |
| PMID 40985996 | A SWOT-Consensus for CAR-T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection. | Hematological oncology | 2025 | name in abstract: lisocabtagene maraleucel |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| P30CA015704 | Cancer Immunology | FRED HUTCHINSON CANCER CENTER | BLEAKLEY, MARIE | 2025–2026 | name in abstract: lisocabtagene maraleucel |
| P30CA016672 | Stem Cell Biology & Cellular Therapy Program | UNIVERSITY OF TX MD ANDERSON CAN CTR | SHPALL, ELIZABETH J | 2019–2026 | name in abstract: lisocabtagene maraleucel |
| R01CA286488 | Enhancing CAR-T cell therapy for DLBCL | WASHINGTON UNIVERSITY | DIPERSIO, JOHN F. | 2026–2026 | name in abstract: liso-cel |
| R01CA309280 | Engineering CD19 mimotopes for enhancing and repurposing CD19-CAR T against hematological malignancies and solid tumors | CHILDREN'S HOSP OF PHILADELPHIA | MA, LEYUAN | 2026–2026 | name in abstract: Breyanzi |
| UG1HL108987 | Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical Centers - UG1 | H. LEE MOFFITT CANCER CTR & RES INST | PIDALA, JOSEPH A | 2024–2026 | name in abstract: lisocabtagene maraleucel |
| UG1HL109137 | Phase III, Multicenter, Randomized, Double-Blind Study of Duvelisib as Cytokine Release Syndrome Prophylaxis in Patients with Large Cell or Mantle Cell Lymphoma Undergoing CAR T-Cell Therapies | WASHINGTON UNIVERSITY | PUSIC, ISKRA | 2024–2026 | name in abstract: lisocabtagene maraleucel |
Notes
Lentiviral anti-CD19 4-1BB CAR with EGFRt, defined CD4:CD8 composition. Juno acquired by Celgene, then BMS.
How to cite
lisocabtagene maraleucel (AXP000016.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000016.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.